WAVE LIFE SCIENCES LTD. Contract Liability (Deferred Revenue)
WAVE LIFE SCIENCES LTD. (WVE) had Contract Liability (Deferred Revenue) of $8.70 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-07-30
- 2026-06-30: Contract with Customer, Liability, Current $8.70M.
- 2026-03-31: Contract with Customer, Liability, Current $9.40M.
- 2025-12-31: Contract with Customer, Liability, Current $44.44M.
- 2025-09-30: Contract with Customer, Liability, Current $46.52M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $8.70M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $9.40M 10-Q · filed 2026-04-28 |
| 2025-12-31 | $44.44M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $46.52M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $51.58M 10-Q · filed 2025-07-30 |
| 2025-03-31 | $57.31M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $65.97M 10-K · filed 2026-02-26 |
| 2024-09-30 | $135.91M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $137.14M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $140.59M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $150.06M 10-K · filed 2025-03-04 |
| 2023-09-30 | $68.25M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $111.13M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $106.96M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $31.56M 10-K · filed 2024-03-06 |
| 2022-09-30 | $32.34M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $37.47M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $36.43M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $37.10M 10-K · filed 2023-03-23 |
| 2021-09-30 | $8.74M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $24.18M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $24.76M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $91.56M 10-K · filed 2022-03-03 |
| 2020-09-30 | $86.19M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $84.85M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $88.04M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $89.65M 10-K · filed 2021-03-04 |
| 2019-09-30 | $96.32M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $97.96M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $105.89M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $100.94M 10-K · filed 2020-03-02 |
| 2018-09-30 | $103.23M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $27.29M 10-Q · filed 2018-08-09 |
| 2017-12-31 | $1.27M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |